drugset / Trial / NCT00424528

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

NCT00424528

Phase 4 Completed 235 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate and compare the efficacy of arformoterol twice a day and tiotropium once a day (dosed sequentially) versus tiotropium once a day alone in subjects with Chronic Obstructive Pulmonary Disease (COPD).

Timeline

Start
2006-12
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Arformoterol Small molecule 15 ug Other
Comparator Tiotropium Other / unclassified 18 ug Other